Skip to main content

Advertisement

Table 2 Distribution of initial treatment by clinical and tumor characteristics.

From: Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1)

      Percent receiving each therapy  
Characteristic Number1 (%) Number2 (%) Radical prostatectomy Radiation therapy Hormonal therapy Watchful waiting P3
Screen-detected          
   Yes 2,106 (63) 2,092 (63) 43.45 34.46 9.70 12.38 <0.0001
   No 864 (26) 855 (26) 31.70 25.73 10.76 31.81  
   Unknown 358 (11) 353 (11) 36.83 27.20 12.46 23.51  
DRE results          
   Normal 1,312 (39) 1,301 (39) 42.51 28.67 9.76 19.06 <0.0001
   Abnormal 1,086 (33) 1,081 (33) 37.47 38.48 11.84 12.21  
   Equivocal/unk 930 (28) 918 (28) 38.34 27.02 9.15 25.49  
PSA value          
   0-4 290 (9) 289 (9) 43.94 28.72 5.19 22.15 <0.0001
   >4-10 1,603 (48) 1,599 (48) 46.78 33.27 7.57 12.38  
   >10-20 617 (19) 608 (18) 33.22 38.82 12.01 15.95  
   >20-50 260 (8) 254 (8) 20.87 35.04 22.83 21.26  
   50+ 111 (3) 111 (3) 20.72 27.03 24.32 27.93  
   Unknown 447 (13) 439 (13) 35.76 15.26 10.25 38.72  
Gleason score          
   2-4 352 (11) 347 (11) 31.70 23.92 7.49 36.89 <0.0001
   5-7 2,475 (74) 2,459 (75) 44.57 30.87 8.95 15.62  
   8-10 289 (9) 285 (9) 25.96 40.70 21.40 11.93  
   Unknown 212 (6) 209 (6) 14.35 37.80 15.31 32.54  
Comorbidity score          
   0 2,772 (83) 2,749 (83) 41.36 32.34 9.28 17.02 <0.0001
   1 441 (13) 437 (13) 33.87 27.69 11.90 26.54  
   2+ 115 (3) 114 (3) 21.93 23.68 28.07 26.32  
  1. 1: Sample size for analysis of conservative versus definite therapy.
  2. 2: Sample size for dividing conservative treatment into hormone therapy and watchful waiting (excludes 28 observations missing dates for hormone therapy). Used for calculating proportions in this table.
  3. 3: Probability from a two-sided X2 test comparing the distribution of treatments across levels of the variable.